ClinicalTrials.gg
Status unknownNCT00008281Updated Jan 6, 2014

Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

A Phase 3 interventional study of FOLFOX regimen and fluorouracil in Colorectal Cancer, sponsored by Sanofi. Status unknown at 134 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-06.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2002), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 159 studies testing fluorouracil in Colorectal Neoplasms — 15 open to participants now, 19 under way, 4 of them phase 3. Fluorouracil · Colorectal Neoplasms.

Started
2000
with 6 others
Phase 3
40 of 159
2 open now
Registered
29th of 159
by date

Among the 159 studies testing fluorouracil in Colorectal Neoplasms, this one is one of 7 that started in 2000, is one of 40 in phase 3, and was the 29th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 159 studies testing fluorouracil in Colorectal Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 159 studies testing fluorouracil in Colorectal Neoplasms, or all of them as a file.
02

Study summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for metastatic colorectal cancer.

PURPOSE: Phase III trial to compare the effectiveness of three chemotherapy regimens in treating patients who have metastatic colorectal cancer.

Read the detailed description

OBJECTIVES: I. Compare the overall survival of patients with metastatic colorectal carcinoma treated with fluorouracil and leucovorin calcium with vs without oxaliplatin vs oxaliplatin alone. II. Compare the response rate, time to tumor-related symptomatic worsening, time to disease progression, onset and duration of complete and partial responses, and duration of disease stabilization in patients treated with these regimens. III. Determine the safety profile of these regimens in these patients.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to Karnofsky performance status (50-60% vs 70-100%), number of metastatic organs (1 vs 2 or more), and LDH value (up to 1.5 times upper limit of normal (ULN) vs greater than 1.5 times ULN). Patients are randomized to one of three treatment arms. Arm I: Patients receive leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 22 hours on days 1 and 2. Arm II: Patients receive oxaliplatin IV over 2 hours on day 1. Arm III: Patients receive oxaliplatin IV concurrently with leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 22 hours on day 1. Leucovorin calcium and fluorouracil are administered alone on day 2 on the same schedule as on day 1. Treatment repeats every 2 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients are followed for 30 days, every 2 weeks for up to 3 months, and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 786 patients (262 per arm) will be accrued for this study within 12 months.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • stage IV colon cancer
  • stage IV rectal cancer
  • recurrent colon cancer
  • recurrent rectal cancer
  • adenocarcinoma of the colon
  • adenocarcinoma of the rectum
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS: or cytologically confirmed adenocarcinoma of the colon or rectum that is not amenable to potentially curative therapy (e.g., inoperable metastatic disease) At least 1 unidimensionally at least 20 mm in diameter by conventional CT or MRI scan or at least 10 mm in diameter by spiral CT scan Progressive disease by CT or MRI scan during or no more than 6 months after the last dose of prior irinotecan, fluorouracil, and leucovorin calcium (Saltz regimen) for metastatic disease

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: 50-100% : Not specified Hematopoietic: at least 1,500/mm3 count at least 100,000/mm3 Hepatic: no greater than 1.5 times (ULN) and ALT no greater than 2 times ULN (no greater than 5 times ULN if liver metastases present) Alkaline phosphatase no greater than 2 times ULN (no greater than 3 times ULN if liver metastases present) Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No uncontrolled high blood pressure No unstable angina, symptomatic congestive heart failure, or serious cardiac arrhythmia No class III or IV heart disease No history of cardiac toxicities with prior fluorouracil and leucovorin calcium No myocardial infarction within the past 6 months Pulmonary: No interstitial pneumonia or extensive and symptomatic fibrosis of the lung Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective during and for 6 months after study No known dihydropyrimidine dehydrogenase deficiency No allergy to platinum-containing drugs No history of intolerance to study anti-emetics (e.g., 5-HT3 antagonists) No known peripheral neuropathy (absence of deep tendon reflexes as sole deficiency allowed) No uncontrolled diabetes No active infection No other active originating from primary site other than colon or rectum

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics One and only 1 prior chemotherapy regimen for metastatic disease consisting of first-line irinotecan, fluorouracil, and leucovorin calcium (Saltz regimen) Prior adjuvant fluorouracil with leucovorin calcium allowed At least 3 weeks since prior chemotherapy for metastatic disease and recovered No prior adjuvant irinotecan No prior oxaliplatin Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to study lesions unless evidence of progressive disease within the radiotherapy port At least 3 weeks since prior radiotherapy Surgery: See Disease Characteristics At least 4 weeks since prior major surgery and recovered Prior surgical resection of primary tumor or metastases allowed Other: At least 30 days since prior drugs No other concurrent investigational agents No other concurrent anti-cancer therapy No concurrent participation in other investigational trials

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
06

Study locations

134 sites
  • Comprehensive Cancer Institute of Huntsville
    Huntsville, Alabama 35801, United States
  • Oncology Center at Providence Park
    Mobile, Alabama 36608, United States
  • Arizona Clinical Research Center
    Tucson, Arizona 85712, United States
  • Arkansas Oncology Associates, P.A.
    Little Rock, Arkansas 72207, United States
  • Offices of Richard Shapiro, Benjamin Stafford, and Sharon J. Yee
    Arcadia, California 91007-7678, United States
  • California Cancer Care, Inc.
    Greenbrae, California 94904, United States
  • Medical Oncology Internal Medicine
    Los Angeles, California 90067, United States
  • Bay Area Tumor Institute
    Oakland, California 94609, United States
  • Medical Oncology Care Associates
    Orange, California 92668, United States
  • P.M.K. Medical Group, Inc.
    Oxnard, California 93030, United States
  • Cancer and Blood Institute of the Desert
    Rancho Mirage, California 92270, United States
  • Kaiser Permanente-Southern California Permanente Medical Group
    San Diego, California 92120, United States
  • Kaiser Permanente Medical Center - Vallejo
    Vallejo, California 94589, United States
  • Kaiser Permanente - Denver
    Denver, Colorado 80205, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • Northwestern Connecticut Oncology-Hematology Associates
    Torrington, Connecticut 06790, United States
  • Lombardi Cancer Center
    Washington, District of Columbia 20007, United States
  • Comprehensive Cancer Care Specialists of Boca Raton
    Boca Raton, Florida 33428, United States
  • Center for Hematology-Oncology
    Boca Raton, Florida 33486, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • University of Florida Health Science Center
    Gainesville, Florida 32610-0296, United States
  • Memorial Regional Hospital Comprehensive Cancer Center
    Hollywood, Florida 33021, United States
  • Florida Community Cancer Center
    Hudson, Florida 34667, United States
  • North Florida Hematology & Oncology Associates
    Jacksonville, Florida 32204, United States
  • Hematology/Oncology Associates
    Jacksonville, Florida 32216, United States
  • Lakeland Regional Medical Center
    Lakeland, Florida 33804, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami, Florida 33140, United States
  • Oncology-Hematology Group of South Florida
    Miami, Florida 33176, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Office of Thomas A. Marsland
    Orange Park, Florida 32073, United States
  • Florida Hospital Cancer Institute
    Orlando, Florida 32804, United States
  • Office of Barry S. Berman
    Orlando, Florida 32806, United States
  • Memorial Hospital West
    Pembroke Pines, Florida 33028, United States
  • Hematology-Oncology Associates, PA
    Pensacola, Florida 32501, United States
  • Hematology/Oncology Associates
    Port Saint Lucie, Florida 34952, United States
  • Oncology & Hematology Associates of West Broward
    Tamarac, Florida 33321, United States
  • Office of Ron D. Schiff
    Tampa, Florida 33613, United States
  • Hematology and Oncology Consultants
    Titusville, Florida 32796, United States
  • Dreyer Medical Clinic
    Aurora, Illinois 60506, United States
  • Northwestern Medical Faculty Foundation
    Chicago, Illinois 60611, United States
  • Hematology Oncology Associates of Illinois-Highland Park
    Highland Park, Illinois 60035, United States
  • Lutheran General Cancer Care Center
    Park Ridge, Illinois 60068, United States
  • Oncology and Hematology Associates
    Greenfield, Indiana 46140, United States
  • Cancer Care Center
    New Albany, Indiana 47150, United States
  • Oncology Associates of Cedar Rapids
    Cedar Rapids, Iowa 52403, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160-7357, United States
  • Cancer Center of Kansas - Wichita
    Wichita, Kansas 67214, United States
  • Albert B. Chandler Medical Center, University of Kentucky
    Lexington, Kentucky 40536-0084, United States
  • James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • Baton Rouge General Medical Center
    Baton Rouge, Louisiana 70821-2511, United States
  • Louisiana Oncology Associates
    Lafayette, Louisiana 70506, United States
  • Physicians Office
    Metairie, Louisiana 70006, United States
  • Louisiana State University School of Medicine
    New Orleans, Louisiana 70112-2822, United States
  • Maine Center for Cancer Medicine and Blood Disorders
    Scarborough, Maine 04074, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201-1379, United States
  • Parker Hughes Cancer Center
    Roseville, Minnesota 55113, United States
  • Park Nicollet Clinic
    St. Louis Park, Minnesota 55416, United States
  • Columbia Comprehensive Cancer Care Clinic
    Columbia, Missouri 65201, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Midwest Oncology Consortium
    Kansas City, Missouri 64111, United States
  • Missouri Baptist Cancer Center
    Saint Louis, Missouri 63131, United States
  • St. John's Mercy Medical Center
    Saint Louis, Missouri 63141, United States
  • Missouri Cancer Care, P.C.
    St. Charles, Missouri 63301, United States
  • Cooper Hospital/University Medical Center
    Voorhees, New Jersey 08043, United States
  • Veterans Affairs Medical Center - Albany
    Albany, New York 12208, United States
  • Albert Einstein Comprehensive Cancer Center
    Bronx, New York 10461, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263-0001, United States
  • North Shore Hematology/Oncology Associates, P.C.
    East Setauket, New York 11733, United States
  • Capitol District Hematology Oncology Associates, P.C.
    Latham, New York 12110-0610, United States
  • St. Vincents Comprehensive Cancer Center
    New York, New York 10011, United States
  • NYU School of Medicine's Kaplan Comprehensive Cancer Center
    New York, New York 10016, United States
  • Interlakes Oncology/Hematology PC
    Rochester, New York 14623, United States
  • State University of New York Health Sciences Center - Stony Brook
    Stony Brook, New York 11790-7775, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Lineberger Comprehensive Cancer Center, UNC
    Chapel Hill, North Carolina 27599-7295, United States
  • Regional Hematology Oncology Associates
    Durham, North Carolina 27704, United States
  • Raleigh Hematology/Oncology Associates - Wake Practice
    Raleigh, North Carolina 27609, United States
  • Piedmont Hematology-Oncology Associates-Triad
    Winston-Salem, North Carolina 27103, United States
  • Hematology Oncology Consultants Inc
    Columbus, Ohio 43235, United States
  • Dayton Oncology/Hematology P.A.
    Dayton, Ohio 45439, United States
  • Naz Medical Center
    Midwest City, Oklahoma 73310, United States
  • Cancer Care Associates
    Tulsa, Oklahoma 74136, United States
  • Willamette Valley Cancer Center
    Eugene, Oregon 97401-8122, United States
  • Abington Memorial Hospital
    Abington, Pennsylvania 19001, United States
  • Oncology/Hematology Associates - Beaver
    Beaver, Pennsylvania 15009, United States
  • University of Pennsylvania Cancer Center
    Philadelphia, Pennsylvania 19104-4283, United States
  • Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
    Philadelphia, Pennsylvania 19107-5541, United States
  • Pennsylvania Oncology Hematology Associates
    Philadelphia, Pennsylvania 19107, United States
  • University of Pittsburgh Cancer Institute
    Pittsburgh, Pennsylvania 15213-3489, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29605, United States
  • Erlanger Health Systems
    Chattanooga, Tennessee 37403, United States
  • Baptist Regional Cancer Center - Knoxville
    Knoxville, Tennessee 37901, United States
  • West Clinic, P.C.
    Memphis, Tennessee 38117, United States
  • Memphis Cancer Center
    Memphis, Tennessee 38119, United States
  • St. Thomas Medical Center
    Nashville, Tennessee 37205, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232-6838, United States
  • Lone Star Oncology
    Austin, Texas 78759, United States
  • Texas Oncology P.A.
    Dallas, Texas 75230-2503, United States
  • Center for Oncology Research and Treatment, Medical City Hospital
    Dallas, Texas 75230, United States
  • Simmons Cancer Center - Dallas
    Dallas, Texas 75235-9154, United States

Showing the first 100 of 134 sites across 2 countries. Choose a country and city above to see the rest.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00008281
Lead sponsor
Sanofi
First posted
Feb 16, 2004
Start date
Oct 2000
Last update
Jan 6, 2014

Study contacts

Mace L. Rothenberg, MD, FACP
study chair · Vanderbilt-Ingram Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2002. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluorouracil · Oxaliplatin

Start the discussion